Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060214 | 0.89 | CYP46A1 (0.53) | CYP46A1NR4A2TDP1CA12CA1 | |
| SCHEMBL1206018 | 0.86 | CYP46A1 (0.57) | CYP46A1NR4A2TDP1CA12CA1 | |
| SCHEMBL12569465 | 0.83 | CPS1 (0.40) | CYP46A1PDK2MAPTALDH1A1NPC1 | |
| SCHEMBL27605075 | 0.83 | CPS1 (0.40) | CYP46A1PDK2MAPTALDH1A1NPC1 | |
| SCHEMBL23243818 | 0.83 | LOXL2 (0.42) | CYP46A1PDK2MAPTHPGDALDH1A1 | |
| SCHEMBL10004074 | 0.83 | CYP46A1 (0.49) | CYP46A1NR4A2CA12CA1CA2 | |
| SCHEMBL29014341 | 0.83 | NPC1 (0.49) | TDP1GAAMAPTHPGDKDM4E | |
| SCHEMBL14012584 | 0.82 | CES2 (0.61) | TDP1CA12CA1CA2CA7 | |
| SCHEMBL523258 | 0.82 | CES2 (0.61) | TDP1CA12CA1CA2CA7 | |
| SCHEMBL7222675 | 0.81 | TSHR (0.53) | TDP1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459932-B2 | KIF18A inhibitors | AMGEN INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4007752-B1 | KIF18A INHIBITORS | AMGEN INC (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4617272-A1 | FUSED BICYCLIC COMPOUND | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025092902-A1 | COMPOUND CONTAINING FUSED BICYCLIC RING, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| WO-2024125626-A1 | NITROGENOUS COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF | NUPHASE THERAPEUTICS (HANGZHOU) LIMITED., CO. (CN) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024099386-A1 | FUSED BICYCLIC COMPOUND | 正大天晴药业集团股份有限公司 | 2024-05-16 | — | — | WO | disclosed |
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYCARMA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYCARMA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| CN-116925065-A | Compounds for inhibiting KIF18A and application thereof | 武汉人福创新药物研发中心有限公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003000692-A2 | OXYTOCIN AGONISTS | FERRING BV (NL) | 2003-01-03 | — | — | WO | disclosed |
| EP-1226122-A1 | BICYCLIC VASOPRESSIN AGONISTS | Ferring BV (NL) | 2002-07-31 | — | — | EP | disclosed |
| WO-2002000626-A1 | FUSED AZEPINE DERIVATIVES AND THEIR USE AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001029005-A1 | BICYCLIC VASOPRESSIN AGONISTS | FERRING BV (NL) | 2001-04-26 | — | — | WO | disclosed |
| US-4753962-A | HYPOGLYCEMIC, ANTIOBESITY AGENT | BEECHAM GROUP P.L.C. (GB) | 1988-06-28 | — | — | US | disclosed |
| US-4654371-A | ANTI-OBESITY, HYPOGLYCEMIA AGENTS | BEECHAM GROUP P.L.C. (GB) | 1987-03-31 | — | — | US | disclosed |
| US-4478849-A | HYPERGLYCEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0006735-B1 | SECONDARY AMINES, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | BEECHAM GROUP PLC (GB) | 1983-06-15 | — | — | EP | disclosed |
| EP-0006735-A1 | Secondary amines, their preparation, pharmaceutical compositions containing them and their use | BEECHAM GROUP PLC (GB) | 1980-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399324-A1 | AGENTS FOR TREATING DISORDERS INVOLVING RYANODINE RECEPTORS | RYR2, RYR1, ATP2A1 | CYP46A1 1600/4885NR4A2 617/4885TDP1 957/4885 |
| US-12459932-B2 | KIF18A inhibitors | KIF18A, KIF18B, KIF15 | CYP46A1 457/4885NR4A2 3024/4885TDP1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.